Koselugo approved in the EU for children with NF1
22 June 2021 07:00 BST Koselugo approved in the EU for children withneurofibromatosis type 1 and plexiform neurofibromas First medicine approved in the EU to treat this rare and debilitating genetic condition SPRINT Phase II trial showed Koselugo reduced tumourvolume, reducing pain and improving quality of life AstraZeneca and MSD's Koselugo (selumetinib) has been granted conditional approval in the European Union (EU) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged three years and